<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width-device-width, initial scale=1">
    <title>SCRI Labkey Server</title>
    <style>
        * { box-sizing: border-box;
            font-size: 1em;
            font-family: Arial, Helvetica, sans-serif;
            background-color: #f1f1f1; }
        body { margin: 0;}

        /* style for header */
        .header { text-align: left;
                  padding: 10px 20px;
                  font-size: 2.5em;
                  font-weight: 500; }

        /* Create two columns that floats next to each other */
        ,column { float: left;
                  width: 50%;
                  padding: 10px 20px;
                  border-style: solid; }

        /* Clear floats after the columns */
        .row:after { content: "";
                     display: table;
                     clear: both; }

        /* Responsive layout - makes the three columns stack on top of each other instead of next to each other */
        @media screen and (max-width:600px) {
            .column { width: 100%; }
        }
    </style>
</head>

<body>
<div class="header">
    <h1>Welcome to the SCRI-CSL LabKey Server!</h1>
</div>

<div class="row">
    <div class="column">
        <h2>Active Clinical Trials</h2>
        <p>CSL currently have six active phase I and II clinical trials.
            Click links below to access the dedicated study sites and to learn more about the studies and PIs</p>
        <table>
            <tbody>
            <tr>
                <p><a href="/project/Correlative%20Studies/CAR%20T%20Clinical%20Trials/Studies/ENCIT-01/begin.view?">
                    ENCIT-01</a></p>
                <table>
                    <tbody>
                    <tr>
                        <td>Official Title:</td>
                        <td>Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01</td>
                    </tr>
                    <tr>
                        <td>Target:</td>
                        <td>L1-CAM+ Recurrent / Refractory Neuroblastoma</td>
                    </tr>
                    <tr>
                        <td>Trial Info:</td>
                        <td><span><a href="https://clinicaltrials.gov/ct2/show/NCT02311621?term=NCT02311621&rank=1" target="_blank">NCT02311621</a></span></td>
                    </tr>
                    <tr>
                        <td>Institution:</td>
                        <td>Seattle Children's</td>
                    </tr>
                    <tr>
                        <td>Clinical PI:</td>
                        <td><span><a href="http://www.seattlechildrens.org/medical-staff/Navin-Robert-Pinto/" target="_blank">Navin R. Pinto, MD</a></span></td>
                    </tr>
                    </tbody>
                </table>
            </tr>
            <tr>
                <p><a href="/project/Correlative%20Studies/CAR%20T%20Clinical%20Trials/Studies/PLAT-02%20visit/begin.view?">
                    PLAT-02</a></p>
                <table>
                    <tbody>
                    <tr>
                        <td>Official Title:</td>
                        <td>Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02:
                            A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia</td>
                    </tr>
                    <tr>
                        <td>Target:</td>
                        <td>CD19+ Acute Leukemia</td>
                    </tr>
                    <tr>
                        <td>Trial Info:</td>
                        <td><span><a href="https://clinicaltrials.gov/ct2/show/NCT02028455?term=NCT02028455&rank=1" target="_blank">NCT02028455</a></span></td>
                    </tr>
                    <tr>
                        <td>Institution:</td>
                        <td>Seattle Children's</td>
                    </tr>
                    <tr>
                        <td>Clinical PI:</td>
                        <td><span><a href="http://www.seattlechildrens.org/medical-staff/rebecca-a-gardner/" target="_blank">Rebecca A. Gardner, MD</a></span></td>
                    </tr>
                    </tbody>
                </table>
            </tr>
            <tr>
                <p><a href="/project/Correlative%20Studies/CAR%20T%20Clinical%20Trials/Studies/PLAT-03/begin.view?">
                    PLAT-03</a></p>
                <table>
                    <tbody>
                    <tr>
                        <td>Official Title:</td>
                        <td>PLAT-03: A Pilot Feasibility and Safety Study of CD19t
                            T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia</td>
                    </tr>
                    <tr>
                        <td>Target:</td>
                        <td>CD19+ Acute Leukemia</td>
                    </tr>
                    <tr>
                        <td>Trial Info:</td>
                        <td><span><a href="https://clinicaltrials.gov/ct2/show/NCT03186118?term=NCT03186118&rank=1" target="_blank">NCT03186118</a></span></td>
                    </tr>
                    <tr>
                        <td>Institution:</td>
                        <td>Seattle Children's</td>
                    </tr>
                    <tr>
                        <td>Clinical PI:</td>
                        <td><span><a href="http://www.seattlechildrens.org/medical-staff/Colleen-Elizabeth-Annesley/" target="_blank">Colleen E. Annesley, MD</a></span></td>
                    </tr>
                    </tbody>
                </table>
            </tr>
            <tr>
                <p><a href="/project/Correlative%20Studies/CAR%20T%20Clinical%20Trials/Studies/PLAT-04/begin.view?">
                    PLAT-04</a></p>
                <table>
                    <tbody>
                    <tr>
                        <td>Official Title:</td>
                        <td>PLAT-04: A Phase 1 Feasibility and Safety Study of CD22 CAR T-Cell Immunotherapy for CD22+ Leukemia</td>
                    </tr>
                    <tr>
                        <td>Target:</td>
                        <td>CD22+ Acute Leukemia</td>
                    </tr>
                    <tr>
                        <td>Trial Info:</td>
                        <td><span><a href="https://clinicaltrials.gov/ct2/show/NCT03244306?term=NCT03244306&rank=1" target="_blank">NCT03244306</a></span></td>
                    </tr>
                    <tr>
                        <td>Institution:</td>
                        <td>Seattle Children's</td>
                    </tr>
                    <tr>
                        <td>Clinical PI:</td>
                        <td><span><a href="http://www.seattlechildrens.org/medical-staff/Corinne-Summers/" target="_blank">Corrine Summers, MD</a></span></td>
                    </tr>
                    </tbody>
                </table>
            </tr>
            <tr>
                <p><a href="/project/Correlative%20Studies/CAR%20T%20Clinical%20Trials/Studies/PLAT-05/begin.view?">
                    PLAT-05</a></p>
                <table>
                    <tbody>
                    <tr>
                        <td>Official Title:</td>
                        <td>PLAT-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22
                            CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma</td>
                    </tr>
                    <tr>
                        <td>Target:</td>
                        <td>CD19+CD22+ Acute Leukemia</td>
                    </tr>
                    <tr>
                        <td>Trial Info:</td>
                        <td><span><a href="https://clinicaltrials.gov/ct2/show/NCT03330691?term=NCT03330691&rank=1" target="_blank">NCT03330691</a></span></td>
                    </tr>
                    <tr>
                        <td>Institution:</td>
                        <td>Seattle Children's</td>
                    </tr>
                    <tr>
                        <td>Clinical PI:</td>
                        <td><span><a href="http://www.seattlechildrens.org/medical-staff/Colleen-Elizabeth-Annesley/" target="_blank">Colleen E. Annesley, MD</a></span></td>
                    </tr>
                    </tbody>
                </table>
            </tr>
            <tr>
                <p><a href="/project/Correlative%20Studies/CAR%20T%20Clinical%20Trials/Studies/BrainChild-01/begin.view?">
                    BrainChild-01</a></p>
                <table>
                    <tbody>
                    <tr>
                        <td>Official Title:</td>
                        <td>Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for
                            HER2 Positive Recurrent/Refractory Pediatric Central Nervous System Tumors</td>
                    </tr>
                    <tr>
                        <td>Target:</td>
                        <td>HER2+ Recurrent / Refractory Central Nervous System (CNS) tumors</td>
                    </tr>
                    <tr>
                        <td>Trial Info:</td>
                        <td><span><a href="https://clinicaltrials.gov/ct2/show/NCT03500991?cond=03500991&rank=1" target="_blank">NCT03500991</a></span></td>
                    </tr>
                    <tr>
                        <td>Institution:</td>
                        <td>Seattle Children's</td>
                    </tr>
                    <tr>
                        <td>Clinical PI:</td>
                        <td><span><a href="http://www.seattlechildrens.org/medical-staff/Nicholas-Alexander-Vitanza/" target="_blank">Nicholas A. Vitanza, MD</a></span></td>
                    </tr>
                    </tbody>
                </table>
            </tr>
            </tbody>
        </table>
    </div>
    <div class="column">
        <h2>CSL Statistics</h2>
        <p>Correlative Studies Lab (CSL) processes research samples from hospitals across the nation
            and around the global for all active clinical trials. Below are some key statistics.</p>
        <table>
            <tbody>
            <tr>
                <td>
                    <div id='plot1'></div>
                    <p>Number of Specimen Sample Processed Year to Date by Trial</p>
                </td>
            </tr>
            <tr>
                <td>
                    <div id='plot2'></div>
                    <p>Number of Specimen Sample Processed Year to Date By Hospitals:</p>
                </td>
            </tr>
            </tbody>
        </table>
    </div>
</div>

</body>
</html>
3
<script type="text/javascript">
var u1side = LABKEY.WebPart.createReportWebpart({
                schemaName: 'lists',
                queryName: 'specimenRegistryTrackingThisYearByTrial',
                reportName: 'specimenRegistryTrackingThisYearByTrial',
                renderTo: 'plot1',
                webPartConfig:{
                    title: '',
                    frame: 'none',
                    suppressRenderErrors: true
                    },
                reportProperties: {
    		    showSection: 'specimenRegistryTrackingThisYearByTrial'
		            }
                });
u1side.render(plot1);
var u2side = LABKEY.WebPart.createReportWebpart({
                schemaName: 'lists',
                queryName: 'specimenRegistryTrackingThisYearBySite',
                reportName: 'specimenRegistryTrackingThisYearBySite',
                renderTo: 'plot2',
                webPartConfig:{
                    title: '',
                    frame: 'none',
                    suppressRenderErrors: true
                    },
                reportProperties: {
    		    showSection: 'specimenRegistryTrackingThisYearBySite'
		            }
                });
u2side.render(plot2);
</script>